Moderna tanks 14% after COVID-19 vaccine maker cuts yearly sales outlook and misses 3rd-quarter expectations
Dinendra Haria/SOPA Images/LightRocket via Getty Images
- Moderna shares fell as much as 14% on Thursday following the COVID vaccine maker's financial update.
- The company cut its 2022 revenue outlook to a range of $18 billion to $19 billion.
- Third-quarter per-share earnings of $2.53 on total revenue of $3.36 billion missed Wall Street's projections.
Moderna shares sharply dropped Thursday after the COVID vaccine maker reduced its 2022 sales guidance and delivered third-quarter financial results that fell short of Wall Street's targets.
Shares fell by as much as 14% to $128 during premarket trade, the weakest price since October 24. The shares on a year-to-date basis had already fallen by 41%.
The company forecast $18 billion to $19 billion in 2022 revenue from its coronavirus vaccine, lower than its previous outlook of around $21 billion. The vaccine is Moderna's sole product that's commercially available.
The "delay of certain deliveries into 2023 due to short-term supply constraints" was cited as the reason for the lowered projection in Moderna's third-quarter report.
Earnings fell by 67% to $2.53 a share and total revenue came in at $3.36 billion, down from $4.97 billion a year earlier.
Analysts polled by FactSet had expected earnings of $3.29 a share on revenue of $3.53 billion for the quarter that ended on September 30.
Moderna said quarterly product sales fell by 35% to $3.1 billion because of the timing of market authorizations for its vaccine boosters and the related manufacturing ramp-up.
The company said it's making progress on its respiratory vaccine pipeline, including potential vaccines against influenza and Respiratory Syncytial Virus, or RSV, which can cause lung and respiratory tract infections.
from Business Insider https://ift.tt/EdSsG8v
No comments